Peptide Initiative

Peptides · Peptide comparison

Cetrorelix vs Ganirelix

Fast-acting GnRH antagonist that stops premature ovulation during IVF cycles

Fast-acting GnRH antagonist that stops premature ovulation during fertility treatment

  • Hormone Support
  • Hormone Support

At a glance

Quick comparison

Dose rangeCetrorelix3–3 mgGanirelix250–250 mcg
FrequencyCetrorelixOnce dailyGanirelixOnce daily
AdministrationCetrorelixSubcutaneous injectionGanirelixSubcutaneous injection
Cycle lengthCetrorelixOngoing/indefiniteGanirelixOngoing/indefinite
Onset speedCetrorelixModerate (1-2 weeks)GanirelixModerate (1-2 weeks)
Evidence levelCetrorelixStrong human trials (Phase 3 or FDA approved)GanirelixStrong human trials (Phase 3 or FDA approved)

Efficacy

Benefit ratings

Ovulation Control

Cetrorelix98%
Ganirelix94%

Cycle Flexibility

Cetrorelix85%
GanirelixNo recorded rating

Side Effect Profile

Cetrorelix80%
GanirelixNo recorded rating

IVF Success Improvement

CetrorelixNo recorded rating
Ganirelix90%

Safety & OHSS Prevention

CetrorelixNo recorded rating
Ganirelix87%

Technical data

Compound specifications

Cetrorelix

Molecular formula
C70H92ClN17O14
Molecular weight
1431.06 Da
Half-life
Approximately 2-6 hours (varies by route of administration)
Bioavailability
~85% (subcutaneous injection)
CAS number
100885-89-0

Ganirelix

Molecular formula
C80H113ClN18O13
Molecular weight
1570.4 g/mol
Half-life
12.8 hours after a single dose; 16.2 hours at steady state
Bioavailability
~91% (subcutaneous injection)
CAS number
124904-93-4

Protocols

Dosing compared

Cetrorelix

Subcutaneous

  • 0.25 mgOnce every 24 hours · From stimulation day 5-6 until the day of hCG (about 4-9 days)The FDA-approved multiple-dose plan. A 0.25 mg shot under the skin each day stops an early LH surge during fertility (IVF) ovarian stimulation. [5]
  • 3 mgSingle dose (one injection) · One dose covers at least 4 days; add 0.25 mg daily after if hCG is delayedThe FDA-approved single-dose plan. One 3 mg shot is given when estrogen levels show the follicles are ready (usually stimulation day 7). It protects against an early LH surge for at least 4 days. [5][6]

Ganirelix

Subcutaneous

  • 250 mcgOnce daily during the mid-to-late follicular phase · Continued daily until the day of hCG administration (typically about 5-9 days)FDA-labeled dose for inhibiting premature LH surges during controlled ovarian stimulation; started after several days of FSH and continued until hCG trigger [4].

Applications

Best suited for

Cetrorelix

Planning IVF with precise ovulation timing
Cetrorelix is particularly well-suited for individuals focused on planning ivf with precise ovulation timing. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Preventing premature egg release during controlled stimulation
Cetrorelix is particularly well-suited for individuals focused on preventing premature egg release during controlled stimulation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Managing polycystic ovary syndrome (PCOS) during fertility treatment
Cetrorelix is particularly well-suited for individuals focused on managing polycystic ovary syndrome (pcos) during fertility treatment. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Ganirelix

Improving IVF or ICSI success rates
Ganirelix is particularly well-suited for individuals focused on improving ivf or icsi success rates. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Preventing premature ovulation during egg retrieval cycles
Ganirelix is particularly well-suited for individuals focused on preventing premature ovulation during egg retrieval cycles. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Controlling ovarian stimulation in women with unpredictable cycles
Ganirelix is particularly well-suited for individuals focused on controlling ovarian stimulation in women with unpredictable cycles. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety profile

Side effects

Cetrorelix

Common

  • Injection site reactions (redness, itching, swelling)
  • Headache
  • Nausea
  • Mild abdominal discomfort
  • Dizziness
  • Allergic reactions (rash, difficulty breathing)
  • Ovarian hyperstimulation syndrome (OHSS) if used with other fertility drugs
  • Ovarian cysts
  • Vaginal bleeding
  • Mood changes
  • Liver enzyme changes
  • Pelvic pain
  • Severe allergic reaction

Serious

  • Severe allergic reaction

Ganirelix

Common

  • Mild discomfort at treatment site
  • Injection site reactions (redness, bruising, swelling)
  • Headaches
  • Abdominal pain
  • Pelvic discomfort
  • Nausea
  • Fatigue or dizziness

Serious

  • Severe allergic reaction

Research status

Safety & evidence

Cetrorelix

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Cetrorelix is an FDA-approved GnRH antagonist used exclusively in assisted reproductive technology with proven safety in short-term reproductive cycles. Unlike GnRH agonists, cetrorelix lacks the initial testosterone flare, making it well-tolerated for ovarian stimulation. Primary side effects are mild and local—injection site reactions (erythema, bruising) occur in 10-20% of patients. No systemic bone loss, cardiovascular complications, or serious adverse events have been reported in the reproductive context where treatment duration is limited (typically 7-10 days). The short treatment window in IVF protocols minimizes long-term safety concerns. Hypersensitivity reactions are rare but possible.

Contraindications

  • Known allergy to cetrorelix or any ingredient
  • Pregnancy (it may harm the developing baby)
  • Undiagnosed vaginal bleeding
  • Severe liver or kidney disease
  • Latex allergy (some syringes contain latex)

Ganirelix

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Ganirelix is an FDA-approved GnRH antagonist whose safety was evaluated in 794 women in two controlled clinical trials, with treatment lasting 1–14 days. [4] Adverse events were infrequent: gynecological abdominal pain 4.8%, headache 3.0%, ovarian hyperstimulation syndrome 2.4%, vaginal bleeding 1.8%, and injection site reactions and nausea 1.1% each. [4] Hypersensitivity reactions, including anaphylaxis, angioedema and urticaria, have been reported after marketing, sometimes with the first dose; the needle shield on some syringes contains natural rubber latex. [4] Because it blocks the GnRH receptor directly, it causes no initial release of gonadotropins. [4]

Contraindications

  • Known or suspected pregnancy [4]
  • Known hypersensitivity to ganirelix or any of its components, including the natural rubber latex needle shield on some syringes [4]
  • Known hypersensitivity to GnRH or any other GnRH analog [4]
  • Ovarian cysts larger than 3cm

Decision guide

Which is right for you?

Cetrorelix

Choose Cetrorelix if…

  • Planning IVF with precise ovulation timing
  • Preventing premature egg release during controlled stimulation
  • Managing polycystic ovary syndrome (PCOS) during fertility treatment

Ganirelix

Choose Ganirelix if…

  • Improving IVF or ICSI success rates
  • Preventing premature ovulation during egg retrieval cycles
  • Controlling ovarian stimulation in women with unpredictable cycles